Fact 7 of 10 in the story · Monday 2 November, 15h05
Coupe-faim : un marché en forte croissance et des effets indésirables nombreux
Le marché des traitements coupe-faim de type GLP-1 explose en France, alors que les effets indésirables rapportés se multiplient.
In brief
Health event (severity: low) nationwide, first detected on 2 November 2026 at 15:05. Reported by 1 source (1 article), last updated on 2 November 2026 at 15:05. Part of the story “Arrival of Wegovy in tablet form and tensions around anti-obesity treatments”.
- Category
- Health
- Severity
- Low
- Place
National
- Detected
- 2 Nov, 15h05
- Updated
- 2 Nov, 15h05
- Reference
- no.8816
What changed in the story at that point
1 article · 1 source · 1 bord sur 3 · outlets: left 0, centre 0, right 1
Story angles
This event does not yet have its own comparison: here is the story's Arrival of Wegovy in tablet form and tensions around anti-obesity treatments.
All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center develops waiting times, the parallel market and patient testimonies, while the right highlights the non-reimbursable nature and practical information (price, side effects).
Left
Highlights the rivalry between Novo Nordisk and Eli Lilly on a fast-growing global market, as well as the lack of reimbursement for the pills and the side effects to be aware of.
Centre
Develops the concrete consequences: waiting times of up to 18 months, the parallel market, the position of drug treatments compared with bariatric surgery and patient testimonies.
Right
Emphasizes the non-reimbursable nature of oral Wegovy and offers a practical format listing price, side effects and reimbursement.
Common points
- =Wegovy in tablet form is available in pharmacies in France from Monday 2 November.
- =The oral version is not reimbursed.
- =Wegovy had previously been administered by injection in France.
Divergences
- ≠The left focuses on competition between laboratories (Novo Nordisk, Eli Lilly), an angle little present on the right.
- ≠The center insists on waiting times of up to 18 months and the parallel market, absent from the left and right headlines provided.
- ≠The center and the right detail price and side effects in a practical format, while the left prioritizes the industrial and regulatory angle.
Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41
Lire les sources · 1 article, 1 source
- 15h05Les ÉchosCentre-rightWirevia Google Actualités France2 NovCoupe-faim : le marché explose, les effets indésirables aussi - Les Echos
Coupe-faim : le marché explose, les effets indésirables aussi Les Echos Le Wegovy, médicament antiobésité, arrive en comprimé dans les pharmacies françaises Le Monde.fr Médicaments anti-obésité GLP-1 : près d'un Français sur cinq prêt à en prendre pour maigrir, pourquoi ce chiffre inquiète Yahoo Life France Chute de cheveux, nausées… les effets secondaires du Wegovy, ce médicament anti obésité vendu désormais en comprimés La Provence Wegovy en comprimés : qui y a le droit, comment en obtenir, combien ça coûte ? La Voix du Nord
Further reading
Organisations cited
Places cited
Keywords
#anti-obésité · #GLP-1 · #marché · #effets indésirables
Go up the thread
In the same story
- Les anti-obésité modifient les habitudes alimentaires des patients3 Nov
- Traitement anti-obésité en comprimé : des effets secondaires sur l'économie3 Nov
- Les douanes renforcent les contrôles face au trafic de coupe-faims comme le Wegovy3 Nov
- Wegovy tablet arrives in French pharmacies2 Nov
- Près d'un Français sur cinq prêt à prendre des anti-obésité GLP-1 pour maigrir2 Nov
- Dijon : les limites du remboursement des traitements anti-obésité2 Nov
People and organisations cited